SimrBio

Shanghai SIMR Biotechnology (SIMR Biotech) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for pain, inflammation, and central nervous system (CNS) disorders. Founded in 2014 and headquartered in Shanghai, the company leverages a proprietary translational medicine platform that integrates patient data and animal models to identify and validate novel drug targets. Its clinical pipeline is led by SR-419, a novel non-opioid analgesic for peripheral neuropathic pain, and SR-750, a GABRA5 negative allosteric modulator for trigeminal neuralgia, both of which are in Phase 2 development. Additionally, the company is advancing SR-1375, an Lp-PLA2 inhibitor, for acute inflammation and diabetic complications. SIMR Biotech has established a global footprint with operations in China, Australia, and the United States, supported by a strong network of venture capital investors.